MyMyelomaTeam

Yes, the effectiveness of the COVID-19 vaccine for multiple myeloma (MM) patients has been studied. Here are some key points:

- Additional Dose Benefits: Research shows that more than half of those with B-cell blood cancers, including multiple myeloma, who did not produce COVID-19 antibodies after the first two doses, did Show Full Answer

Yes, the effectiveness of the COVID-19 vaccine for multiple myeloma (MM) patients has been studied. Here are some key points:

- Additional Dose Benefits: Research shows that more than half of those with B-cell blood cancers, including multiple myeloma, who did not produce COVID-19 antibodies after the first two doses, did produce antibodies after a third dose. Those who did produce antibodies after the first two doses had an improved antibody response after the third dose.

- Recommendations: The Leukemia & Lymphoma Society recommends that people with blood cancer who are fully vaccinated get an additional dose of the vaccine.

- Eligibility for Boosters: People with multiple myeloma who are considered immunocompromised may be eligible for a third dose of the Pfizer or Moderna vaccines at least 28 days following their second dose. If not considered immunocompromised, they may be eligible for a booster six months after the second dose, depending on age and other health conditions.

- Mix and Match Boosters: Health agencies have approved "mix and match" boosters, meaning a person may receive initial doses of one type of COVID-19 vaccine and a booster of another.

For the most accurate and personalized advice, it's important to consult with a healthcare provider.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Are People With Myeloma Eligible for Moderna and Johnson & Johnson Booster Shots? | MyMyelomaTeam

Myeloma Awareness: How To Get Involved | MyMyelomaTeam